Get the Stockscreener App
2.05
3.76%
-0.08
After Hours:
2.00
-0.05
-2.44%
Tscan Therapeutics Inc Stock (TCRX) Latest News
TScan Therapeutics to Participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference - GlobeNewswire
Inside TScan's Revolutionary TCR Cell Therapy Pipeline: CEO Conference Presentation Revealed - StockTitan
abrdn plc Has $2.69 Million Stake in TScan Therapeutics, Inc. (NASDAQ:TCRX) - MarketBeat
TScan Therapeutics: Finding Their Footing After An Eventful ASH Meeting (NASDAQ:TCRX) - Seeking Alpha
TScan Therapeutics, Inc. (NASDAQ:TCRX) Short Interest Update - MarketBeat
TScan Therapeutics, Inc. (NASDAQ:TCRX) Shares Purchased by JPMorgan Chase & Co. - Defense World
Barclays PLC Purchases 44,903 Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World
TScan Therapeutics' SWOT analysis: innovative t-cell therapy stock faces pivotal year - MSN
TScan Therapeutics, Inc.'s (NASDAQ:TCRX) recent 14% pullback adds to one-year year losses, institutional owners may take drastic measures - Simply Wall St
Here's Why TScan Therapeutics (TCRX) is Poised for a Turnaround After Losing -5.63% in 4 Weeks - MSN
TScan Therapeutics (NASDAQ:TCRX) & bluebird bio (NASDAQ:BLUE) Head-To-Head Survey - Defense World
Jane Street Group LLC Decreases Position in TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World
TScan Therapeutics, Inc. (NASDAQ:TCRX) Shares Acquired by Barclays PLC - Defense World
TScan Therapeutics, Inc. (NASDAQ:TCRX) Shares Bought by Geode Capital Management LLC - Defense World
State Street Corp Has $3.77 Million Holdings in TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World
TScan Therapeutics Announces $30 Million Registered Direct OfferingOn December 26, 2024, TScan Therapeutics, Inc. (NASDAQ: TCRX) entered into a securities purchase agreement with Lynx1 Capital Management LP, an existing shareholder, and an inve - Defense World
TScan Therapeutics, Inc. (NASDAQ:TCRX) Stock Position Increased by Stifel Financial Corp - Defense World
TScan secures $30 million through warrant sale to Lynx1 By Investing.com - Investing.com Nigeria
TScan Therapeutics Refinances Existing Debt Facility with Silicon Valley Bank - Defense World
TScan Shares Jump 23% on Securities Purchase Agreement - MarketWatch
TScan Therapeutics announces ~$30M direct offering - MSN
TScan secures $30 million through warrant sale to Lynx1 - Investing.com
TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium - The Manila Times
TScan Therapeutics (TCRX) Secures $30M Premium-Priced Financing, Extends Cash Runway to 2027 - StockTitan
With 52% ownership, TScan Therapeutics, Inc. (NASDAQ:TCRX) boasts of strong institutional backing - Yahoo Finance
Recent Research Analysts’ Ratings Updates for TScan Therapeutics (TCRX) - Defense World
TScan Therapeutics’ (TCRX) “Outperform” Rating Reaffirmed at Wedbush - Defense World
Wedbush Reiterates "Outperform" Rating for TScan Therapeutics (NASDAQ:TCRX) - MarketBeat
TScan Therapeutics Secures $52.5M Loan from SVB - TipRanks
TScan Therapeutics Refinances Existing Convertible Debt - GlobeNewswire
TScan Therapeutics Secures Major $52.5M Financing Deal to Extend Cash Runway Through 2026 - StockTitan
XTX Topco Ltd Makes New Investment in TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World
2 "Strong Buy"-Rated Biotech Stocks With 303% To 446% Upside Potential - Barchart
Tscan Therapeutics Inc (TCRX-Q) QuotePress Release - The Globe and Mail
tScan Therapeutics sees $385,768 purchase by Lynx1 Capital - Investing.com
Lynx1 Capital Management LP Increases Stake in TScan Therapeutics Inc - GuruFocus.com
TScan Therapeutics' SWOT analysis: TCR-T stock shows promise amid challenges - Investing.com India
TScan Therapeutics' SWOT analysis: TCR-T stock shows promise amid challenges By Investing.com - Investing.com South Africa
Wedbush Cuts Earnings Estimates for TScan Therapeutics - Defense World
Equities Analysts Offer Predictions for TCRX FY2026 Earnings - MarketBeat
TScan Therapeutics (NASDAQ:TCRX) Earns Buy Rating from Needham & Company LLC - Defense World
HC Wainwright Reaffirms Buy Rating for TScan Therapeutics (NASDAQ:TCRX) - Defense World
0.53%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):